What is Augustine Therapeutics?
Augustine Therapeutics is a biopharmaceutical company dedicated to creating innovative treatments for neuromuscular, neurodegenerative, and cardiometabolic diseases. Their core technology revolves around a novel non-hydroxamate, non-hydrazine chemotype for HDAC6 inhibitors, designed to offer enhanced specificity and reduced toxicity compared to earlier compounds. The company's pipeline includes AGT-100XXX, currently undergoing IND-enabling studies, positioning Augustine Therapeutics at the forefront of chronic disease therapeutic development.
How much funding has Augustine Therapeutics raised?
Augustine Therapeutics has raised a total of $85M across 1 funding round:
Series A
$85M
Series A (2025): $85M with participation from Novo Holdings, PMV, AdBio Partners, Eli Lilly, K.U.Leuven, V-Bio Ventures, and Asabys Partners
Key Investors in Augustine Therapeutics
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on life sciences and healthcare investments.
PMV
PMV is a Flemish investment company that finances promising companies from their inception through growth and internationalization, offering venture capital and other financial solutions.
AdBio Partners
AdBio Partners is a European venture capital firm specializing in early-stage investments within the life sciences sector, supporting promising startups.
What's next for Augustine Therapeutics?
The recent major strategic investment signals a strong validation of Augustine Therapeutics' scientific approach and therapeutic potential. This capital infusion is expected to accelerate the advancement of their lead program, AGT-100XXX, through critical IND-enabling stages and potentially into clinical trials. The company's focus on addressing unmet needs in chronic diseases, coupled with experienced leadership, suggests a trajectory aimed at significant market impact and further strategic partnerships or financing rounds as their pipeline matures.
See full Augustine Therapeutics company page
